Vertex’s CRISPR Gene Therapy CASGEVY Gains Expanded FDA Approval for Sickle Cell Disease and Beta Thalassemia in Children Ages 2 and Older

July 5, 2026

Vertex Pharmaceuticals USA

Overview

Vertex Pharmaceuticals announced the US FDA has approved an expanded indication for its gene therapy, CASGEVY® (exagamglogene autotemcel), for treating sickle cell disease or transfusion-dependent beta thalassemia in patients aged 2 years and older. This marks CASGEVY as the first CRISPR gene therapy approved for these severe blood disorders in such a young pediatric population. The expanded approval is projected to make this one-time, transformative treatment available to an additional 5,500 patients in the US.

In Depth

Key Findings

Vertex Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted expanded approval for its CRISPR/Cas9-based gene therapy, CASGEVY® (exagamglogene autotemcel), to include the treatment of patients aged 2 years and older with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). This milestone represents the first gene therapy approved for these debilitating blood disorders in the youngest pediatric cohort to date, potentially making this one-time curative treatment available to an estimated 5,500 additional patients in the United States.

Technical & Clinical Details

CASGEVY is an autologous ex-vivo cell gene therapy that involves collecting a patient’s own hematopoietic stem cells and editing a specific region of the Bcl11a gene using CRISPR/Cas9 technology. This genetic modification reactivates the production of fetal hemoglobin (HbF), which is naturally present only during fetal development. HbF effectively compensates for the defective hemoglobin S (HbS) in SCD or the deficient beta-globin chains in TDT. In clinical trials, over 90% of evaluable SCD patients achieved sustained freedom from severe vaso-occlusive crises (VOCs), and more than 80% of TDT patients achieved transfusion independence, demonstrating a robust efficacy profile alongside a manageable safety profile.

Background & Context

Sickle cell disease and beta thalassemia are severe inherited blood disorders affecting millions globally. Historically, allogeneic hematopoietic stem cell transplantation (HSCT) was the only potential cure, but it was limited by donor availability and significant risks of transplant-related complications. The expanded approval of CASGEVY is a monumental achievement for CRISPR gene editing technology in clinical application, particularly its extension to young children. This early intervention has the potential to halt disease progression and dramatically improve long-term quality of life. This technology establishes a new therapeutic paradigm for genetic disorders and is expected to accelerate research into its application for other genetic conditions.

Strategic Significance & Outlook

The expanded approval of CASGEVY is expected to have a profound impact on the entire gene therapy sector, further galvanizing the development of other CRISPR-based treatments. Vertex has stated its commitment to scaling access programs and manufacturing capabilities to reach more eligible patients. As long-term safety and efficacy data continue to accrue, the clinical value of CASGEVY will become even clearer. This success also paves the way for the development of gene-editing therapies for a broader spectrum of rare and common diseases, fundamentally transforming the future landscape of regenerative medicine and offering unprecedented hope for patients with previously intractable conditions.

Source: https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-expanded-use-casgevyr-treatment

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.